Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in children aged less than 15 years in Guinea-Bissau - An open-label non-inferiority randomised clinical trial

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Ursing, Johan ^a,b,c   Rombo, Lars ^b,d,e   Rodrigues, Amabelia ^a   Kofoed, Poul Erik ^a,f  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b KAROLINSKA INSTITUTE   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d Sormland County Council   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f KOLDING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ARTHRALGIA; ARTICLE; CHILD; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEEDING DIFFICULTY; FEMALE; GUINEA-BISSAU; HEART PALPITATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; NONHUMAN; PARASITE CLEARANCE; PARASITE IDENTIFICATION; PLASMODIUM FALCIPARUM; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SLEEP DISORDER; STOMACH PAIN; MALARIA, FALCIPARUM; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; CHILD; ETHANOLAMINES; FLUORENES; GUINEA-BISSAU; HUMANS; MALARIA, FALCIPARUM; QUINOLINES; TREATMENT OUTCOME;

EID: 84994031487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161495     Document Type: Article

References (21)

1. WHO. World Malaria Report. 2014.
2. WHO. Guidelines for the treatment of malaria (Third edition). 2015.
3. Ursing J, Kofoed PE, Rodrigues A, Blessborn D, Thoft-Nielsen R, Bjorkman A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrinefor treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2011; 203(1): 109-16. Epub 2010/12/15. doi: jiq001 [pii] doi: 10.1093/infdis/jiq001 PMID: 21148503.
4. Ursing J, Rombo L, Rodrigues A, Aaby P, Kofoed PE. Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortality. PLoS One. 2014; 9(7): e101167. Epub 2014/07/02. doi: 10.1371/journal.pone.0101167 PMID: 24984039; PubMed Central PMCID: PMC4077730.
5. Kofoed PE, Mapaba E, Lopes F, Pussick F, Aaby P, Rombo L. Comparison of 3,5 and 7 days' treatment with Quinimax for falciparum malaria in Guinea-Bissau. Trans RSocTrop MedHyg. 1997; 91 (4): 462-4. Epub 1997/07/01. PMID: 9373656.
6. Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A. 2008; 105(37): 14216-21. Epub 2008/09/11. [pii] doi: 10.1073/pnas.0804628105 PMID: 18780786.
7. Sylla K, Abiola A, Tine RC, Faye B, Sow D, Ndiaye JL, et al. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis. 2013; 13: 598. Epub 2013/12/21. doi: 10.1186/1471-2334-13-598 PMID: 24354627; PubMed Central PMCID: PMC3878220.
8. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrineversus dihydroartemisinin-pipera-quine for the treatment of malaria. Clin Infect Dis. 2014; 59(4): 509-16. Epub 2014/05/16. doi: 10.1093/cid/ciu353 PMID: 24825870.
9. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquinefor treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One. 2008; 3(6): e2390. Epub 2008/06/12. doi: 10.1371/journal.pone.0002390 PMID: 18545692; PubMed Central PMCID: PMC2405936.
10. Four Artemisinin-Based Combinations Study G. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011; 8(11): e1001119. Epub 2011/11/17. doi: 10.1371/journal.pmed.1001119 PMID: 22087077; PubMed Central PMCID: PMC3210754.
11. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-pipera-quine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009; 4(11): e7871. Epub 2009/11/26. doi: 10.1371/journal.pone.0007871 PMID: 19936217; PubMed Central PMCID: PMC2776302.
12. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am J Trop Med Hyg. 2007; 76(5): 844-8. Epub 2007/05/10. 76/5/844 [pii]. PMID: 17488902.
13. Jovel IT, Kofoed PE, Rombo L, Rodrigues A, Ursing J. Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012. Antimicrob Agents Chemother. 2015; 59(2): 872-9. Epub 2014/11/26. doi: 10.1128/AAC.03554-14 PubMed Central PMCID: PMC4335894. PMID: 25421474
14. Project BH Available from: http://www.bandim.org/.
15. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. 2007.
16. WHO. Methods for surveillance of antimalarial drug efficacy 2009. Available from: http://www.who.int/malaria/publications/atoz/9789241597531/en/.
17. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J. 2014; 13: 32. Epub 2014/01/29. doi: 10.1186/1475-2875-13-32 PMID: 24468007; PubMed Central PMCID: PMC3909240.
18. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009; 53(12): 5069-73. Epub 2009/09/23. [pii] doi: 10.1128/AAC.00638-09 PMID: 19770282.
19. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquinefor treatment of malaria: a randomized trial. PLoS Clin Trials. 2007; 2(5): e20. Epub 2007/05/26. doi: 10.1371/journal.pctr.0020020 PMID: 17525792; PubMed Central PMCID: PMC1876597.
20. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, et al. Efficacy and safety of artemether-lumefantrineand dihydroartemisinin-piperaquinein the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J. 2014; 13: 33. Epub 2014/01/30. doi: 10.1186/1475-2875-13-33 PMID: 24472156; PubMed Central PMCID: PMC3916309.
21. Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tappero J, et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. The American journal of tropical medicine and hygiene. 2010; 83(4): 873-5. Epub 2010/10/05. doi: 10.4269/ajtmh.2010.10-0158 PMID: 20889882; PubMed Central PMCID: PMC2946759.